Trial · NCT07891169
Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid Tumors
NCT07891169, Not applicable, Active not recruiting, National Cancer Center, Korea
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid Tumors. Trials, record NCT07891169. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891169
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid Tumors
- NCT number
- NCT07891169
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 2,800 participants, estimated
- Lead sponsor
- National Cancer Center, Korea
- Conditions
Advanced Solid Tumors, Metastatic Solid Tumors, Locally Advanced Solid Tumors, Recurrent Solid Tumors, Proteogenomic Screening and Molecular Signaling, Basket Clinical Trial Framework, Targeted Therapy Based on HRD (Homologous Recombination Deficiency) and ALK/ROS1/MET Signatures
- Interventions
- Homologous Recombination Deficiency (HRD), ALK/ROS1/MET, standard care treatment
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of Successful Identification of Actionable Therapeutic Targets | From the date of pre-treatment tissue sample collection until the completion of proteogenomic analysis and report generation, assessed up to 3 weeks (21 days) per participant. | The percentage of subjects whose proteogenomic profiles-characterized through integrated Whole Exome Sequencing (WES) and phosphoproteomic analysis of fresh-frozen (FF) specimens-allow for the identification of actionable therapeutic targets for enrollment in specific basket trial sub-protocols (e.g., HRD or ALK/ROS1/MET) |
| Secondary | Logistical Success Rate of Fresh-Frozen (FF) Specimen Transport | From the time of tissue collection at participating hospitals until receipt and quality control verification at the central biobank, assessed up to 14 days per specimen. | The proportion of collected specimens that successfully meet the strict Cold Ischemia Time (CIT) requirements (the interval from extraction to freezing) as part of the established nationwide delivery and logistics system |
| Secondary | Progression-Free Survival (PFS) and Overall Survival (OS) | From enrollment until disease progression or death from any cause, whichever occurs first, assessed up to 5 years. | Evaluation of survival outcomes relative to the identified proteogenomic profiles and subsequent treatment assignments using Kaplan-Meier estimates and Cox-proportional hazards regression |
| Secondary | Frequency and Distribution of Molecular Signature | From enrollment through completion of molecular signature profiling for all participants, assessed up to 36 months. | Descriptive characterization of the frequency of targetable molecular variants and proteogenomic signatures across various advanced solid tumor types |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891169
GET https://conductscience.org/api/trials/v1/NCT07891169/registered